Plain-English translation of NCT07093606 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying whether , a medication used to treat immune thrombocytopenia (a condition where your body doesn't produce enough blood-clotting cells called platelets), causes liver damage in patients who take it. Researchers will monitor liver health in about 100 adults receiving this treatment to understand how often and how severely liver problems occur.
While this medication is helpful for treating low platelet counts, doctors want to better understand whether it can harm the liver—especially in people who already have liver stress from diabetes or fatty liver disease. This study will help doctors know what liver tests to watch for and how carefully to monitor patients during treatment.
You likely qualify if…
You likely don't qualify if…
You would take tablets as prescribed by your doctor for your platelet condition. Throughout your treatment, you'll have regular blood tests done to check your liver function and see whether the medication is affecting your liver. The study team will track your results and monitor you to catch any liver problems early if they occur.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
Egypt
Sohag University
Enrollment target
~100 participants
Started
July 2025
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peter A Alfy, Resident
Sohag University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.